ID   K562/GM-CSF
SY   K562 GM-CSF; K562GM-CSF; GM-K562
DR   Wikidata; Q107115522
RX   PubMed=10466632;
RX   PubMed=23170257;
RX   PubMed=32289117;
CC   Population: Caucasian.
CC   Biotechnology: Used for the production of the Sorento Therapeutics STI-6991 SARS-CoV-2 (COVID-19) vaccine candidate. The cell line which is lethally irradiated is used to produce the recombinant SARS-CoV-2 spike protein rSARS-CoV-2 which is the active part of the vaccine formulation (PubMed=32289117).
CC   Characteristics: Does not express HLA class I or II antigens, potentially decreasing the magnitude of the alloresponses generated on repeated immunizations (PubMed=10466632).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 2434; CSF2.
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 6
RX   PubMed=10466632; DOI=10.1089/10430349950017347;
RA   Borrello I., Sotomayor E.M., Cooke S., Levitsky H.I.;
RT   "A universal granulocyte-macrophage colony-stimulating
RT   factor-producing bystander cell line for use in the formulation of
RT   autologous tumor cell-based vaccines.";
RL   Hum. Gene Ther. 10:1983-1991(1999).
RX   PubMed=23170257; DOI=10.4161/onci.20954;
RA   Brusic A., Hainz U., Wadleigh M., Neuberg D., Su M., Canning C.M.,
RA   DeAngelo D.J., Stone R.M., Lee J.-S., Mulligan R.C., Ritz J.,
RA   Dranoff G., Sasada T., Wu C.J.-Y.;
RT   "Detecting T-cell reactivity to whole cell vaccines: proof of concept
RT   analysis of T-cell response to K562 cell antigens in CML patients.";
RL   OncoImmunology 1:1095-1103(2012).
RX   PubMed=32289117; DOI=10.1016/j.medidd.2020.100026;
RA   Ji H., Yan Y., Ding B.-B., Guo W.-Z., Brunswick M., Niethammer A.G.,
RA   SooHoo W., Smith R., Nahama A., Zhang Y.-L.;
RT   "Novel decoy cellular vaccine strategy utilizing transgenic
RT   antigen-expressing cells as immune presenter and adjuvant in vaccine
RT   prototype against SARS-CoV-2 virus.";
RL   Med. Drug Discov. 5:100026.1-100026.2(2020).